Search results for "Hepatocellular carcinoma"


 
Results 1 - 10 of about 15 for "Hepatocellular carcinoma".

From ACP Internist Weekly

Potential benefits of lipophilic statins appeared to be dose- and duration-dependent, with the greatest reduction in hepatocellular carcinoma risk seen with use of a moderate-dose statin for about two ... Lipophilic statins were associated with
August 2019

Regorafenib now FDA-approved to treat hepatocellular carcinoma

Approved use of the drug has been expanded to include treatment of patients with hepatocellular carcinoma who have been treated with sorafenib. ... The FDA has approved the first treatment for hepatocellular carcinoma in nearly a decade, the agency
May 2017

Statins associated with reduced mortality risk in hepatocellular carcinoma

Patients with hepatocellular carcinoma (HCC) who take statins after diagnosis may have a lower risk for death, a recent study found.
January 2019

MKSAP quiz: HCV-related cirrhosis with decompensation

Liver transplantation is the only curative therapy for hepatocellular carcinoma and for end-stage liver disease. ... washout meets radiologic criteria for hepatocellular carcinoma and, therefore, does not require a lesion biopsy.
March 2019

Spotlight on hepatocellular cancer

Overall, 2,140 (95.2%) patients achieved a sustained virologic response, and 78 (3.5%) patients developed hepatocellular carcinoma during a mean follow-up of 14 months. ... cholangiocarcinoma and hepatocellular carcinoma, and one (1%) developed both
April 2018

From ACP Journal Club

19 Annals of Internal Medicine. Decompensation is complications of advanced cirrhosis that affect morbidity and mortality (e.g., variceal hemorrhage, ascites, hepatic encephalopathy, hepatorenal syndrome, and hepatocellular carcinoma).
August 2019

Spotlight on cirrhosis

Patients with cirrhosis were the focus of several recent studies, which reviewed the evidence behind nutritional assessment, calculated the cost-effectiveness of hepatocellular carcinoma screening, and estimated the prevalence of nonalcoholic
February 2017

Daily aspirin may reduce risk of hepatitis-related liver cancer

A Taiwanese nationwide cohort study of more than 10,000 patients with chronic hepatitis B showed a statistically significant 29% risk reduction for hepatocellular carcinoma in patients who received daily aspirin ... Daily aspirin may be associated with a
March 2019

Spotlight on mortality trends in liver disease

hepatocellular carcinoma increased by 2.1% per year (95% CI, 1.9% to 2.3%; P<0.001) during the study period. ... For hepatocellular carcinoma, women experienced a consistent increase in related mortality while death rates among men slowed after 2011.
July 2018

Spotlight on direct-acting antivirals

Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection are associated with higher survival rates after liver transplantation and lower all-cause mortality and hepatocellular carcinoma (HCC) incidence, but not ... damage and
February 2019

Result Page: Prev   1   2   Next